| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Roland W Herzog | |
| P2860 | cites work | Nonredundant roles of IL-10 and TGF-β in suppression of immune responses to hepatic AAV-factor IX gene transfer | Q42786561 |
| Tilt balance towards regulation: evolving new strategy for treatment of hemophilia inhibitors | Q42839182 | ||
| Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery | Q44861538 | ||
| Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter | Q45457148 | ||
| Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors | Q45736630 | ||
| Recombinant adeno-associated virus for muscle directed gene therapy | Q45764433 | ||
| Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce | Q45864205 | ||
| Muscle as a target for supplementary factor IX gene transfer | Q45869069 | ||
| Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. | Q45869966 | ||
| Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer | Q45874902 | ||
| Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation | Q45879591 | ||
| Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. | Q45879597 | ||
| Major role of local immune responses in antibody formation to factor IX in AAV gene transfer | Q45883516 | ||
| Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy | Q45888356 | ||
| Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment | Q46124719 | ||
| Oral Tolerance: Another Reason to Eat Your Veggies! | Q49740101 | ||
| Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin. | Q50622853 | ||
| Gene Therapy for Hemophilia. | Q51057724 | ||
| Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B | Q21245486 | ||
| Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome | Q24625426 | ||
| Clinical development of gene therapy: results and lessons from recent successes | Q26743393 | ||
| Targeted approaches to induce immune tolerance for Pompe disease therapy | Q26767363 | ||
| Mechanism of oral tolerance induction to therapeutic proteins | Q26866369 | ||
| Gene therapy for hemophilia | Q28081911 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| AAV2 gene therapy readministration in three adults with congenital blindness. | Q30587265 | ||
| Translational Data from AAV-Mediated Gene Therapy of Hemophilia B in Dogs | Q30882233 | ||
| Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs | Q30891500 | ||
| Early clinical data raise the bar for hemophilia gene therapies | Q31136058 | ||
| Hepatic gene transfer as a means of tolerance induction to transgene products | Q33775537 | ||
| Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers | Q33782809 | ||
| Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. | Q33931862 | ||
| Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions | Q33938435 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy | Q34289040 | ||
| Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia. | Q34424570 | ||
| Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer. | Q40417058 | ||
| Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B. | Q40485786 | ||
| Liver-Specific Allergen Gene Transfer by Adeno-Associated Virus Suppresses Allergic Airway Inflammation in Mice | Q40674938 | ||
| Insulin B chain 9-23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs. | Q40895314 | ||
| Dystrophin immunity in Duchenne's muscular dystrophy. | Q41590387 | ||
| Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. | Q41722852 | ||
| Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect | Q41827136 | ||
| Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer | Q41920883 | ||
| Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. | Q41972673 | ||
| Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells | Q42362478 | ||
| A Cure For Hemophilia: the Promise Becomes a Reality | Q42367183 | ||
| Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy | Q34541550 | ||
| Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells | Q34574858 | ||
| The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation | Q34657284 | ||
| B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study | Q34763584 | ||
| Long-term safety and efficacy of factor IX gene therapy in hemophilia B. | Q34783922 | ||
| Development of Gene Transfer for Induction of Antigen-specific Tolerance | Q34794525 | ||
| Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer | Q34985105 | ||
| Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance | Q34985424 | ||
| Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. | Q34994506 | ||
| The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver | Q35067592 | ||
| Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses | Q35080090 | ||
| AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice | Q35153203 | ||
| Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells | Q35348677 | ||
| Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer | Q35561776 | ||
| Systemic administration of AAV8-α-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression | Q35568510 | ||
| Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg. | Q35583409 | ||
| Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse | Q35803520 | ||
| Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model | Q35847459 | ||
| Systemic protein delivery by muscle-gene transfer is limited by a local immune response | Q35847626 | ||
| Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver | Q35848563 | ||
| Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector | Q35872651 | ||
| Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein | Q35943644 | ||
| Factor VIII gene variants and inhibitor risk in African American hemophilia A patients | Q35953537 | ||
| Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease | Q35988683 | ||
| Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. | Q36007714 | ||
| MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV | Q36142477 | ||
| Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice | Q36144935 | ||
| Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning | Q36164927 | ||
| FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. | Q36243815 | ||
| Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. | Q36438711 | ||
| The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. | Q36440058 | ||
| Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease | Q36543422 | ||
| Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A. | Q36571141 | ||
| Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector | Q36582796 | ||
| CpG-depleted adeno-associated virus vectors evade immune detection. | Q36966955 | ||
| Immune responses to AAV vectors: overcoming barriers to successful gene therapy | Q36983740 | ||
| Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid | Q37043507 | ||
| Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy | Q37066228 | ||
| Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy | Q37071092 | ||
| Liver type I regulatory T cells suppress germinal center formation in HBV-tolerant mice | Q37240657 | ||
| Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice | Q37292357 | ||
| Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies | Q37342834 | ||
| Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression | Q37384103 | ||
| Inhibitors of factor VIII in black patients with hemophilia | Q37385316 | ||
| Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors | Q37385999 | ||
| The role of apoptosis in immune hyporesponsiveness following AAV8 liver gene transfer | Q37393827 | ||
| The miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids | Q37495470 | ||
| Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies | Q37621530 | ||
| B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. | Q37694653 | ||
| Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. | Q37701838 | ||
| Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction | Q37717893 | ||
| Antigen-presenting cell function in the tolerogenic liver environment. | Q37802751 | ||
| The complex and evolving story of T cell activation to AAV vector-encoded transgene products | Q37814051 | ||
| Progress toward inducing immunologic tolerance to factor VIII. | Q38090391 | ||
| The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer | Q38539938 | ||
| In vivo induction of regulatory T cells for immune tolerance in hemophilia | Q38574966 | ||
| In vivo tissue-tropism of adeno-associated viral vectors | Q38824171 | ||
| Innovating immune tolerance induction for haemophilia. | Q38894155 | ||
| Early interaction of adeno-associated virus serotype 8 vector with the host immune system following intramuscular delivery results in weak but detectable lymphocyte and dendritic cell transduction | Q38946187 | ||
| Continuous CD8⁺ T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery | Q38959186 | ||
| Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice | Q39084223 | ||
| The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders. | Q39177966 | ||
| Potential for cellular stress response to hepatic factor VIII expression from AAV vector | Q39293496 | ||
| Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer | Q39302902 | ||
| Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. | Q39501844 | ||
| Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation | Q40188801 | ||
| The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose | Q40296362 | ||
| Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency. | Q40358542 | ||
| P577 | publication date | 2017-05-29 | |
| P1433 | published in | Cellular Immunology | Q2597167 |
| P1476 | title | Complexity of immune responses to AAV transgene products - Example of factor IX. |
| Q90732125 | AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice |
| Q90468943 | Alpha 1 Antitrypsin Gene Therapy Extends the Lifespan of Lupus-Prone Mice |
| Q92547654 | Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity |
| Q98164401 | Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins |
| Q52721830 | Gene Therapy With Regulatory T Cells: A Beneficial Alliance. |
| Q92863312 | Immune Response Mechanisms against AAV Vectors in Animal Models |
| Q45875675 | Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A. |
| Q88166600 | Liver induced transgene tolerance with AAV vectors |
| Q92345037 | Liver-Directed but Not Muscle-Directed AAV-Antibody Gene Transfer Limits Humoral Immune Responses in Rhesus Monkeys |
| Q91636324 | Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV |
| Q88594211 | Modulation of immune responses in lentiviral vector-mediated gene transfer |
| Q90595648 | Update on clinical gene therapy for hemophilia |
| Q93123497 | Use of Heterologous Vesiculovirus G Proteins Circumvents the Humoral Anti-envelope Immunity in Lentivector-Based In Vivo Gene Delivery |
Search more.